Curated News
By: NewsRamp Editorial Staff
July 30, 2026
Datavault AI Expands Healthcare Data Licensing Deal with DataMeds
TLDR
- Datavault AI gains 19.9% equity stake in DataMEDS, expanding into commercial healthcare and wellness for first-mover advantage.
- The amended agreement replaces preferred shares with common shares and extends PharmacyChain blockchain tech to healthcare, enabling patient-controlled data monetization.
- Patients gain control over their health data access and monetization, empowering them in wellness and healthcare decisions.
- Datavault AI's blockchain tech now targets healthspan and wellness, leveraging IoT and AI for remote patient monitoring.
Impact - Why it Matters
This news matters because it signals a significant shift towards patient-controlled health data, allowing individuals to own, access, and monetize their medical information. As healthcare becomes increasingly digitized, this technology could empower patients, improve data security, and foster new revenue models. The expansion also highlights the growing intersection of blockchain, AI, and healthcare, potentially leading to more personalized and efficient care while addressing privacy concerns.
Summary
In a strategic move to broaden its footprint in the healthcare sector, Datavault AI (NASDAQ: DVLT) has expanded its definitive licensing agreement with DataMeds AI Inc., extending its PharmacyChain blockchain technology beyond pharmaceutical distribution into commercial healthcare, healthspan, and wellness applications. This expansion aims to empower patients with control over their health data, enabling access, monetization, and real-world asset tokenization across pharmacy, medical, laboratory, and wearable device environments. The agreement leverages a behavioral healthcare patent portfolio that focuses on medical logistics, IoT population health, and AI-driven remote patient monitoring.
Under the amended terms, Datavault AI will receive common shares representing approximately 19.9% of DataMEDS’ outstanding common stock upon closing of previously announced related transactions, replacing the preferred shares originally planned for tax optimization. This move is designed to accelerate the deployment of Datavault AI’s technology into the healthcare sector, targeting opportunities within the rapidly expanding global health and wellness market while enabling new patient-controlled data transaction models. The companies emphasize that this collaboration will drive innovation in data management and monetization within the healthcare ecosystem.
Datavault AI is known for its AI-driven data experiences, valuation, and monetization of assets in the Web 3.0 environment, with divisions in Acoustic Sciences and Data Sciences. The Acoustic Sciences division features patents like WiSA(R) and ADIO(R), while the Data Science division leverages Web 3.0 and high-performance computing for data perception and monetization. The company’s platform serves multiple industries, including healthcare, biotech, and fintech. The expanded agreement is expected to position Datavault AI at the forefront of patient-controlled health data management, aligning with the growing trend of decentralized data ownership and secure monetization.
Source Statement
This curated news summary relied on content disributed by NewMediaWire. Read the original source here, Datavault AI Expands Healthcare Data Licensing Deal with DataMeds
